Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

The prospective addition of valproic acid to stable antiretroviral therapy reduced the frequency of resting CD4+ T-cell infection in a minority of volunteers. In patients in whom resting CD4+ T-cell infection depletion was observed, viremia was rarely detectable by single copy assay.